Skip to main content
    O

    Orthopediatrics Corp (KIDS)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $31.50
    -0.85 (-2.63%)

    Market Cap: $844.67M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Orthopediatrics Corp (KIDS) Earnings: Report Dates and Results

    Updated Oct 27, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Orthopediatrics (KIDS) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Orthopediatrics reported EPS of -$0.23, above the -$0.25 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    58%(21/36)
    Avg Surprise
    -2.51%
    Streak
    7 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.22
    Range-$0.25 - -$0.18
    10 analysts
    Revenue Consensus
    $70.39M
    Range$67.13M - $72.97M
    10 analysts
    Reports Apr 28, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.30
    Range-$0.41 - -$0.12
    5 analysts
    EPS Revisions
    1
    2
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.28-8.1%
    60d ago-$0.28-8.1%
    30d ago-$0.28-8.1%
    7d ago-$0.28-8.1%
    Current-$0.30
    Revenue Consensus
    $66.93M
    Range$65.99M - $69.30M
    7 analysts

    Next Report

    KIDS has an expected report date of Feb 24, 2027.

    KIDS Earnings Call

    The latest KIDS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 36 quarters below that had an estimate, KIDS beat 21, missed 13 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $72.66M, up 18.6% from $61.25M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.23-$0.25-$0.25 - -$0.16+8.00%BeatN/A60 up, 3 downOct 27, 2026$72.66M
    Jun 30, 2026-$0.26-$0.31-$0.38 - -$0.17+16.13%BeatN/A61 up, 2 downAug 4, 2026$70.51M
    Mar 31, 2026-$0.42-$0.44-$0.55 - -$0.31+4.55%BeatN/A61 up, 2 downApr 30, 2026$59.36M
    Dec 31, 2025-$0.26-$0.37-$0.40 - -$0.16+29.73%BeatN/A61 up, 1 downFeb 26, 2026$61.60M
    Sep 30, 2025-$0.24-$0.26-$0.27 - -$0.24+7.69%BeatN/A41 up, 2 downOct 28, 2025$61.25M
    Jun 30, 2025-$0.11-$0.28-$0.38 - -$0.17+60.71%BeatN/A40 up, 2 downAug 5, 2025$61.08M
    Mar 31, 2025-$0.39-$0.43-$0.50 - -$0.26+9.30%BeatN/A40 up, 1 downMay 7, 2025$52.41M
    Dec 31, 2024-$0.29-$0.26-$0.34 - -$0.20-12.97%MissN/A32 up, 0 downMar 4, 2025$52.67M
    Sep 30, 2024-$0.18-$0.19-$0.30 - -$0.13+5.26%BeatN/A60 up, 0 downNov 6, 2024$54.57M
    Jun 30, 2024-$0.23-$0.26-$0.38 - -$0.17+11.54%BeatN/A70 up, 0 downAug 5, 2024$52.80M
    Mar 31, 2024-$0.34-$0.40-$0.53 - -$0.27+15.00%BeatN/A70 up, 1 downMay 6, 2024$44.69M
    Dec 31, 2023-$0.23-$0.28-$0.36 - -$0.24+17.86%BeatN/A70 up, 0 downMar 6, 2024$37.61M
    Sep 30, 2023-$0.13-$0.20-$0.26 - -$0.17+35.00%BeatN/A70 up, 0 downNov 6, 2023$39.97M
    Jun 30, 2023-$0.19-$0.20-$0.31 - -$0.16+5.00%BeatN/A71 up, 0 downJul 31, 2023$39.56M
    Mar 31, 2023-$0.29-$0.34-$0.44 - -$0.31+14.71%BeatN/A71 up, 0 downMay 1, 2023$31.59M
    Dec 31, 2022-$0.35-$0.25-$0.34 - -$0.19-40.00%MissN/A70 up, 0 downFeb 28, 2023$30.99M
    Sep 30, 2022-$0.05-$0.21-$0.27 - -$0.15+76.19%BeatN/A71 up, 0 downOct 31, 2022$34.95M
    Jun 30, 2022-$0.17-$0.18-$0.26 - -$0.18+5.56%BeatN/A70 up, 0 downAug 3, 2022$32.93M
    Mar 31, 2022-$0.30-$0.37-$0.44 - -$0.28+18.92%BeatN/A70 up, 0 downMay 4, 2022$23.42M
    Dec 31, 2021-$0.24-$0.30-$0.39 - -$0.17+20.00%BeatN/A7N/AMar 2, 2022$24.81M
    Sep 30, 2021-$0.15-$0.23-$0.45 - -$0.18+34.78%BeatN/A73 up, 0 downNov 3, 2021$25.08M
    Jun 30, 2021-$0.11-$0.33-$0.47 - -$0.19+66.67%BeatN/A7N/AAug 4, 2021$26.70M
    Mar 31, 2021-$0.25-$0.25-$0.35 - -$0.120.00%In lineN/A7N/AMay 5, 2021$21.46M
    Dec 31, 2020-$0.73-$0.27-$0.36 - -$0.19-170.37%MissN/A7N/AMar 10, 2021$18.92M
    Sep 30, 2020-$0.19-$0.31-$0.38 - -$0.24+38.71%BeatN/A7N/ANov 4, 2020$22.20M
    Jun 30, 2020-$0.49-$0.38-$0.51 - -$0.25-28.95%MissN/A7N/AAug 5, 2020$13.59M
    Mar 31, 2020-$0.30-$0.22-$0.40 - -$0.18-36.36%MissN/A6N/AMay 5, 2020$16.36M
    Dec 31, 2019-$0.29-$0.22-$0.35 - -$0.20-31.82%MissN/A8N/AMar 4, 2020$18.95M
    Sep 30, 2019-$0.20-$0.16-$0.21 - -$0.13-25.00%MissN/A6N/ANov 7, 2019$20.74M
    Jun 30, 2019-$0.17-$0.08-$0.13 - -$0.05-112.50%MissN/A7N/AAug 7, 2019$18.20M
    Mar 31, 2019-$0.21-$0.17-$0.21 - -$0.13-23.53%MissN/A6N/AMay 8, 2019$14.66M
    Dec 31, 2018-$0.19-$0.19-$0.24 - -$0.120.00%In lineN/A6N/AMar 6, 2019$14.57M
    Sep 30, 2018-$0.15-$0.12-$0.16 - -$0.06-25.00%MissN/A5N/AOct 31, 2018$15.82M
    Jun 30, 2018-$0.21-$0.15-$0.17 - -$0.06-40.00%MissN/A5N/AAug 8, 2018$15.08M
    Mar 31, 2018-$0.41-$0.30-$0.37 - -$0.12-36.67%MissN/A4N/AMay 14, 2018$12.09M
    Dec 31, 2017-$3.82-$0.17-$0.24 - -$0.13N/AN/AN/A4N/AMar 7, 2018$11.68M
    Sep 30, 2017-$0.13-$0.12N/A-8.33%MissN/AN/AN/AOct 16, 2017$12.38M
    Jun 30, 2017-$0.23N/AN/AN/AN/AN/AN/AN/AAug 10, 2017$11.80M
    Last 38 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.00, after -$1.04 the year before. It was -$4.18 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.00N/A
    Dec 31, 2024-$1.04N/A
    Dec 31, 2023-$0.84N/A
    Dec 31, 2022-$0.87N/A
    Dec 31, 2021-$0.75N/A
    Dec 31, 2020-$1.71N/A
    Dec 31, 2019-$0.87N/A
    Dec 31, 2018-$0.96N/A
    Dec 31, 2017-$4.18N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 10,000 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 202610,00212
    2026Q2Jun 30, 20268,65913
    2026Q1Mar 31, 20267,78212
    2025Q4Dec 31, 20255,51810
    2025Q3Sep 30, 20256,3378
    2025Q2Jun 30, 20255,2806
    2025Q1Mar 31, 20258,0309
    2024Q4Dec 31, 20246,3488

    2026Q3 Earnings Call

    Opening remarks

    Trip Taylor Company Representative Thank you for joining today's call. With me from the company are David R. Bailey, president and chief executive officer, and Fred L. Hite, chief operating and financial officer. Before we begin today, let me remind you that the company's remarks include forward-looking statements within the meaning of federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 2000. These forward-looking statements are subject to numerous risks and uncertainties, and the company's actual results may differ materially. For a discussion of those risk factors, I encourage you to review the company's most recent annual report on Form 10-K, which was filed with the SEC on March 4, 2026, and its subsequent quarterly reports on Form 10-Q. During the call today, management will also discuss certain non-GAAP financial measures, which are supplemental measures of performance. The company believes these measures provide useful information for investors in evaluating its operations period over period. For each non-GAAP financial measure referenced on this call, the company has included a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures in its third-quarter earnings release. Please note that the non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for OrthoPediatrics' financial results prepared in accordance with GAAP. In addition, the content on this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, today, October 27, 2026. Except as required by law, the company undertakes no obligation to revise or update any statements to reflect events or circumstances taking place after the date of this call. With that, I would like to turn the call over to David R. Bailey, president and chief executive officer.

    David R. Bailey President and CEO Thanks, Trip. Good afternoon, everyone, and thank you for joining us today. This was an outstanding quarter for OrthoPediatrics. I want to begin with the metric that matters most to us. During the quarter, we helped nearly 42,000 children, bringing our total impact to over 1.4 million kids helped. I am proud of what our team and our clinical partners continue to accomplish. We are reaching more patients each day with our pediatric-focused products, increasing the quality of care, and improving outcomes for kids around the world. For the third quarter, we delivered record revenue of $72.7 million, up 19% over the prior year, with substantial growth across all of our businesses. Ongoing share gains across our legacy product portfolio served as a key driver alongside robust implant demand, a rapidly growing OPSB franchise, and strong overall international results.

    Frequently Asked Questions About KIDS

    When is Orthopediatrics's next earnings date?

    Orthopediatrics's next earnings report is expected for Feb 24, 2027.

    Did KIDS beat earnings estimates last quarter?

    Yes. Orthopediatrics reported EPS of -$0.23 for the quarter ended Sep 30, 2026, above the -$0.25 estimate, a 8.00% surprise.

    What EPS do analysts expect from KIDS next quarter?

    The consensus EPS estimate for Orthopediatrics for the quarter ending Dec 31, 2026 is -$0.22 from 10 analysts, with estimates from -$0.25 to -$0.18.

    How often does KIDS beat earnings estimates?

    Orthopediatrics beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +15.39%.